SRRK

Scholar Rock is positioned to launch apitegromab as the first muscle-targeted therapy for SMA, pending FDA approval by September 30, 2026. Manufacturing setbacks were production-based, not due to drug efficacy or safety; the alternate fill-finish facility mitigates approval risk but does not eliminate it. SAPPHIRE trial data support apitegromab's add-on value in SMA, showing statistically significant motor function gains over placebo for nonambulatory patients.

Scholar Rock NASDAQ: SRRK CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA, following a resubmitted biologics license application supported by an alternate fill-finish manufacturing facility.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to purchase an aggregate of 14,889 shares of common stock and inducement restricted stock units, covering an aggregate of 37,058 shares of its common stock. The awards are subject to all terms and conditions and other provis.

Scholar Rock said on Friday it would remove Catalent's Indiana manufacturing facility from its application seeking ​FDA approval for a rare neuromuscular disease drug.

Scholar Rock NASDAQ: SRRK said its resubmitted biologics license application for apitegromab remains on track for a U.S. Food and Drug Administration decision by its Sept. 30 PDUFA date, as the company prepares for a potential launch of the muscle-targeted treatment for spinal muscular atrophy, or SMA.

Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today reported financial results for the second quarter ended June 30, 2026, and provided an update on recent company developments. “We are on the threshold of securing the world's first ever regulatory approval of a myostatin inhibitor, whi.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, announced today that it will present new clinical data and research updates at Cure SMA's Annual SMA Research & Clinical Care Meeting being held June 24-26, 2026, in Orlando,.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 134,345 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to purchase an aggregate of 50,936 shares of common stock and inducement restricted stock units, covering an aggregate of 83,409 shares of its common stock. The awards are subject to all terms and conditions and other provi.

Scholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript